Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free BPCP Stock Alerts

BioPharma Credit (BPCP) Competitors

BioPharma Credit logo
GBX 71.92 -1.53 (-2.09%)
As of 11:14 AM Eastern
Compare

BPCP vs. ATST, EMG, 3IN, JGGI, and PHLL

Should you buy BioPharma Credit stock or one of its competitors? BioPharma Credit's main competitors and comparable companies include Alliance Trust (ATST), Man Group (EMG), 3i Infrastructure (3IN), JPMorgan Global Growth & Income (JGGI), and Petershill Partners (PHLL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "capital markets" industry.

How does BioPharma Credit compare to Alliance Trust?

Alliance Trust (LON:ATST) and BioPharma Credit (LON:BPCP) are both finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Alliance Trust pays an annual dividend of GBX 26 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.7%. Alliance Trust pays out 1,226.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

Alliance Trust has higher revenue and earnings than BioPharma Credit. Alliance Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alliance Trust£652.76M0.00£601.66M£2.12N/A
BioPharma Credit£95.48M10.35£130.67M£6.7710.62

BioPharma Credit has a net margin of 92.32% compared to Alliance Trust's net margin of 92.17%. Alliance Trust's return on equity of 17.93% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
Alliance Trust92.17% 17.93% 10.95%
BioPharma Credit 92.32%9.57%5.33%

Alliance Trust has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.176, indicating that its stock price is 82% less volatile than the broader market.

6.9% of Alliance Trust shares are owned by institutional investors. Comparatively, 23.7% of BioPharma Credit shares are owned by institutional investors. 2.4% of Alliance Trust shares are owned by company insiders. Comparatively, 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alliance Trust's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Alliance Trust Neutral
BioPharma Credit Neutral

Summary

Alliance Trust beats BioPharma Credit on 7 of the 12 factors compared between the two stocks.

How does BioPharma Credit compare to Man Group?

BioPharma Credit (LON:BPCP) and Man Group (LON:EMG) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

BioPharma Credit has a beta of 0.176, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Man Group has a beta of 0.631, suggesting that its stock price is 37% less volatile than the broader market.

23.7% of BioPharma Credit shares are owned by institutional investors. Comparatively, 47.5% of Man Group shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Comparatively, 7.5% of Man Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.7%. Man Group pays an annual dividend of GBX 17.02 per share and has a dividend yield of 5.4%. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Man Group pays out 60.6% of its earnings in the form of a dividend.

Man Group has higher revenue and earnings than BioPharma Credit. BioPharma Credit is trading at a lower price-to-earnings ratio than Man Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£95.48M10.35£130.67M£6.7710.62
Man Group£1.69B2.12£382.68M£28.1011.16

Man Group has a consensus target price of GBX 304.75, indicating a potential downside of 2.82%. Given Man Group's stronger consensus rating and higher probable upside, analysts plainly believe Man Group is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Man Group
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

BioPharma Credit has a net margin of 92.32% compared to Man Group's net margin of 18.60%. Man Group's return on equity of 20.36% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.32% 9.57% 5.33%
Man Group 18.60%20.36%4.61%

In the previous week, Man Group had 2 more articles in the media than BioPharma Credit. MarketBeat recorded 2 mentions for Man Group and 0 mentions for BioPharma Credit. Man Group's average media sentiment score of 0.67 beat BioPharma Credit's score of 0.00 indicating that Man Group is being referred to more favorably in the news media.

Company Overall Sentiment
BioPharma Credit Neutral
Man Group Positive

Summary

Man Group beats BioPharma Credit on 14 of the 18 factors compared between the two stocks.

How does BioPharma Credit compare to 3i Infrastructure?

BioPharma Credit (LON:BPCP) and 3i Infrastructure (LON:3IN) are both finance companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.7%. 3i Infrastructure pays an annual dividend of GBX 13.05 per share and has a dividend yield of 3.4%. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. 3i Infrastructure pays out 40.8% of its earnings in the form of a dividend.

BioPharma Credit has a beta of 0.176, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, 3i Infrastructure has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

3i Infrastructure has higher revenue and earnings than BioPharma Credit. BioPharma Credit is trading at a lower price-to-earnings ratio than 3i Infrastructure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£95.48M10.35£130.67M£6.7710.62
3i Infrastructure£301M11.71£347M£32.0011.94

23.7% of BioPharma Credit shares are held by institutional investors. Comparatively, 24.2% of 3i Infrastructure shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Comparatively, 0.1% of 3i Infrastructure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled 3i Infrastructure'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
3i Infrastructure Neutral

3i Infrastructure has a net margin of 92.78% compared to BioPharma Credit's net margin of 92.32%. 3i Infrastructure's return on equity of 10.77% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.32% 9.57% 5.33%
3i Infrastructure 92.78%10.77%4.83%

3i Infrastructure has a consensus target price of GBX 450, suggesting a potential upside of 17.80%. Given 3i Infrastructure's stronger consensus rating and higher probable upside, analysts plainly believe 3i Infrastructure is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
3i Infrastructure
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

3i Infrastructure beats BioPharma Credit on 14 of the 16 factors compared between the two stocks.

How does BioPharma Credit compare to JPMorgan Global Growth & Income?

BioPharma Credit (LON:BPCP) and JPMorgan Global Growth & Income (LON:JGGI) are both finance companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

BioPharma Credit has a beta of 0.176, suggesting that its share price is 82% less volatile than the broader market. Comparatively, JPMorgan Global Growth & Income has a beta of 0.783, suggesting that its share price is 22% less volatile than the broader market.

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled JPMorgan Global Growth & Income'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
JPMorgan Global Growth & Income Neutral

BioPharma Credit has a net margin of 92.32% compared to JPMorgan Global Growth & Income's net margin of 91.40%. BioPharma Credit's return on equity of 9.57% beat JPMorgan Global Growth & Income's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.32% 9.57% 5.33%
JPMorgan Global Growth & Income 91.40%7.63%10.62%

JPMorgan Global Growth & Income has higher revenue and earnings than BioPharma Credit. BioPharma Credit is trading at a lower price-to-earnings ratio than JPMorgan Global Growth & Income, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£95.48M10.35£130.67M£6.7710.62
JPMorgan Global Growth & Income£255.23M13.45£625.87M£41.8115.04

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.7%. JPMorgan Global Growth & Income pays an annual dividend of GBX 22.90 per share and has a dividend yield of 3.6%. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. JPMorgan Global Growth & Income pays out 54.8% of its earnings in the form of a dividend.

23.7% of BioPharma Credit shares are held by institutional investors. Comparatively, 7.1% of JPMorgan Global Growth & Income shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Comparatively, 0.2% of JPMorgan Global Growth & Income shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

JPMorgan Global Growth & Income beats BioPharma Credit on 9 of the 13 factors compared between the two stocks.

How does BioPharma Credit compare to Petershill Partners?

Petershill Partners (LON:PHLL) and BioPharma Credit (LON:BPCP) are both finance companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Petershill Partners' average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
Petershill Partners Neutral
BioPharma Credit Neutral

BioPharma Credit has a net margin of 92.32% compared to Petershill Partners' net margin of 67.97%. Petershill Partners' return on equity of 16.42% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
Petershill Partners67.97% 16.42% 5.95%
BioPharma Credit 92.32%9.57%5.33%

Petershill Partners pays an annual dividend of GBX 15.50 per share and has a dividend yield of 5.0%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.7%. Petershill Partners pays out 17.9% of its earnings in the form of a dividend. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Petershill Partners presently has a consensus target price of GBX 309, indicating a potential downside of 0.48%. Given Petershill Partners' stronger consensus rating and higher possible upside, research analysts clearly believe Petershill Partners is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petershill Partners
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Petershill Partners has higher revenue and earnings than BioPharma Credit. Petershill Partners is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petershill Partners£1.15B2.93£420.55M£86.433.59
BioPharma Credit£95.48M10.35£130.67M£6.7710.62

Petershill Partners has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, BioPharma Credit has a beta of 0.176, suggesting that its share price is 82% less volatile than the broader market.

3.7% of Petershill Partners shares are held by institutional investors. Comparatively, 23.7% of BioPharma Credit shares are held by institutional investors. 0.1% of Petershill Partners shares are held by company insiders. Comparatively, 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Petershill Partners beats BioPharma Credit on 10 of the 15 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCP vs. The Competition

Export
MetricBioPharma CreditCapital Markets IndustryFinance SectorLON Exchange
Market Cap£988.15M£5.67B£14.11B£2.88B
Dividend Yield7.34%7.39%5.87%6.10%
P/E Ratio10.6238.4029.39368.46
Price / Sales10.351,254.74517.4483,426.45
Price / Cash98.0048.2830.4227.89
Price / Book0.733.742.847.08
Net Income£130.67M£417.12M£1.31B£5.89B
7 Day Performance-1.79%0.38%0.63%0.54%
1 Month Performance0.54%1.34%1.58%3.02%
1 Year Performance9.80%6.49%11.85%64.50%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCP
BioPharma Credit
N/AGBX 71.92
-2.1%		N/A+12.1%£988.15M£95.48M10.62N/A
ATST
Alliance Trust
N/AN/AN/AN/A£3.58B£652.76M600.003
EMG
Man Group
2.2453 of 5 stars		GBX 311.80
-0.1%		GBX 304.75
-2.3%		+94.7%£3.57B£1.69B11.101,790
3IN
3i Infrastructure
N/AGBX 384.50
flat		GBX 450
+17.0%		+9.2%£3.55B£301M12.02N/A
JGGI
JPMorgan Global Growth & Income
N/AGBX 638.50
+0.4%		N/A+10.0%£3.48B£255.23M15.27N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCP) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel